Meeting
2022 ASCO Annual Meeting
A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.
Presenter
Sara Michele Federico, MD
St. Jude Children's Research Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03786783
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10003)
DOI
10.1200/JCO.2022.40.16_suppl.10003
Abstract #
10003
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial.
Speaker: Mark A. Ranalli, MD
Videos & Slides
2023 ASCO Annual Meeting
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
Speaker: Holger N. Lode, MD, PhD
Speaker: Stephanie B. Wheeler, PhD, MPH
Speaker: Panel Discussion